California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
EAST RUTHERFORD, N.J., Feb. 05, 2016 -- Cambrex Corporation (NYSE:CBM) announced that fourth quarter 2015 financial results will be released on Tuesday, February 9, 2016 before the market opens.
The Company will host a conference call to discuss the financial results.
Fourth Quarter 2015 Earnings Conference Call
When: Tuesday, February 9, 2016 at 8:30 a.m. Eastern Time
Dial-in: 1-800-905-0392 for U.S.
1-785-830-1913 for International
Passcode: 2549872
Dial-in Replay: 1-888-203-1112 for U.S.
1-719-457-0820 for International
Passcode: 2549872
Available through Tuesday, February 16, 2016
Webcast: www.cambrex.com
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Phone: 201.804.3037 Email: [email protected]
